Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results
Sangamo Therapeutics reported Q3 2020 financial results, showing revenues of $57.8 million, up from $22.0 million in Q3 2019. The company achieved a $30 million milestone from Pfizer for dosing the first patient in the Phase 3 AFFINE study for hemophilia A gene therapy. Cash and equivalents increased to $694.6 million. Despite a net loss of $1.6 million (or $0.01 per share), down from a loss of $27.3 million in the prior year, operating expenses rose to $61.5 million. The company revised its operating expense guidance for 2020 to $210 to $220 million.
- Revenue increased to $57.8 million in Q3 2020, up from $22.0 million in Q3 2019.
- Achieved a $30 million milestone from Pfizer for dosing the first patient in the Phase 3 AFFINE study.
- Cash and equivalents rose to $694.6 million as of September 30, 2020.
- Net loss of $1.6 million in Q3 2020, although significantly reduced from $27.3 million in Q3 2019.
- Operating expenses increased to $61.5 million in Q3 2020, up from $51.2 million in Q3 2019.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights.
“We are pleased with the clinical execution momentum across our portfolio, including the first patient dosed in the registrational AFFINE study of our investigational hemophilia A gene therapy partnered with Pfizer, as well as dosing of the first two patients in the Phase 1/2 STAAR study evaluating our Fabry disease gene therapy,” said Sandy Macrae, CEO of Sangamo. “We also continue to advance our research projects, exemplified by the completion of our research activities in our ALS program partnered with Pfizer.”
Business Updates
-
Earned a
$30 million milestone from Pfizer for the dosing of the first patient in the registrational Phase 3 AFFINE study of investigational hemophilia A gene therapy giroctocogene fitelparvovec (SB-525). - Pfizer provided updated data from the Phase 1/2 Alta study of giroctocogene fitelparvovec demonstrating tolerability, clinically meaningful factor levels with no bleeds and no prophylactic factor use through up to 85 weeks in the longest patient treated in the highest dose cohort.
- Completed dosing of the first two patients in our Phase 1/2 STAAR study evaluating our investigational ST-920 gene therapy in Fabry disease.
- Received additional regulatory approvals supporting the first-in-human Phase 1/2 STEADFAST study evaluating our CAR-Treg product candidate TX200 in kidney transplantation.
-
Completed our research activities in our collaboration with Pfizer to develop gene regulation therapies using zinc finger protein transcription factors for the treatment of C9ORF72-related Amyotrophic Lateral Sclerosis (ALS). Earned a
$5 million milestone related to the program. - Appointed Dr. Kenneth Hillan MB ChB, to our Board of Directors.
Third Quarter 2020 Financial Results
Cash, cash equivalents and marketable securities were
Consolidated net loss attributable to Sangamo for the third quarter ended September 30, 2020 was
Three Months Ended September |
|
Nine Months Ended September |
||||||||||||||
| (In millions) |
|
2020 |
|
2019 |
|
|
|
2020 |
|
2019 |
|
|||||
| Research and development | $ |
45.3 |
$ |
36.3 |
|
$ |
128.3 |
$ |
107.6 |
|
||||||
| General and administrative |
|
16.2 |
|
14.9 |
|
|
50.2 |
|
46.6 |
|
||||||
| Total operating expenses |
|
61.5 |
|
51.2 |
|
|
178.5 |
|
154.2 |
|
||||||
| Stock-based compensation expense |
|
(6.7 |
) |
|
(4.7 |
) |
|
(19.1 |
) |
|
(14.1 |
) |
||||
| Non-GAAP operating expenses | $ |
54.8 |
$ |
46.5 |
|
$ |
159.4 |
$ |
140.1 |
|
||||||
Total operating expenses were
Revised Financial Guidance for 2020
We are revising our full year operating expense guidance initially provided on February 28, 2020 and revised on August 5, 2020 as follows:
(In millions) |
Initially Provided February 28, 2020;
|
Revised on August 5, 2020 |
Updated on November 4, 2020 |
|||
Estimated GAAP Operating Expenses |
|
|
|
|||
Estimated Non-GAAP Operating Expenses* |
|
|
|
|||
*(excludes estimated stock-based compensation of |
||||||
Conference Call
Sangamo will host a conference call today, November 4, 2020, at 5:00 p.m. Eastern Time, which will be open to the public. The call will also be webcast with live Q&A and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.
The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 2575067. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 2575067.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit www.sangamo.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding Sangamo’s current expectations. These forward-looking statements include, without limitation, statements relating to the potential clinical benefits and long-term durability of SB-525 therapy, anticipated plans and timelines of Sangamo and its collaborators for conducting clinical trials, the potential to receive milestone payments under our collaborations with Pfizer and the timing of such payments, Sangamo’s financial resources and expectations, Sangamo’s 2020 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic on the global business environment, healthcare systems and business and operations of Sangamo and its collaborators, including the initiation and operation of clinical trials; the research and development process; the uncertain timing and unpredictable results of clinical trials, including whether final clinical trial data will validate the safety and efficacy of product candidates; the regulatory approval process for clinical trials and product candidates; the manufacturing of products and product candidates; the commercialization of approved products; the potential for technological developments that obviate technologies used by Sangamo and its collaborators; the potential for Sangamo or its collaborators to breach or terminate collaboration agreements; the potential for Sangamo to fail to realize its expected benefits of its collaborations; and Sangamo’s ability to achieve expected future financial performance.
There can be no assurance that Sangamo and its collaborators will be able to develop commercially viable products. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in the operations and business environments of Sangamo and its collaborators. These risks and uncertainties are described more fully in Sangamo’s Securities and Exchange Commission filings and reports, including in Sangamo’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
Non-GAAP Financial Measures
To supplement Sangamo’s financial results and guidance presented in accordance with GAAP, Sangamo presents non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Sangamo believes that this non-GAAP financial measure, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Sangamo’s results from period to period and to its forward-looking guidance, and to identify operating trends in Sangamo’s business. Sangamo has excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Sangamo encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information, to more fully understand Sangamo’s business.
| SELECTED CONSOLIDATED FINANCIAL DATA | ||||||||||||||||
| (unaudited; in thousands, except per share data) | ||||||||||||||||
| Statement of Operations Data: | ||||||||||||||||
Three months ended |
Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
|||||
| Revenues | $ |
57,763 |
|
$ |
21,958 |
|
$ |
92,392 |
|
$ |
47,577 |
|
||||
| Operating expenses: | ||||||||||||||||
| Research and development |
|
45,287 |
|
|
36,288 |
|
|
128,289 |
|
|
107,593 |
|
||||
| General and administrative |
|
16,177 |
|
|
14,918 |
|
|
50,223 |
|
|
46,633 |
|
||||
| Total operating expenses |
|
61,464 |
|
|
51,206 |
|
|
178,512 |
|
|
154,226 |
|
||||
| Loss from operations |
|
(3,701 |
) |
|
(29,248 |
) |
|
(86,120 |
) |
|
(106,649 |
) |
||||
| Interest and other income, net |
|
2,430 |
|
|
1,887 |
|
|
5,910 |
|
|
6,729 |
|
||||
| Loss before taxes |
|
(1,271 |
) |
|
(27,361 |
) |
|
(80,210 |
) |
|
(99,920 |
) |
||||
| Income tax expense |
|
(237 |
) |
|
— |
|
|
(237 |
) |
|
— |
|
||||
| Net loss |
|
(1,508 |
) |
|
(27,361 |
) |
|
(80,447 |
) |
|
(99,920 |
) |
||||
| Net income (loss) attributable to non-controlling interests |
|
42 |
|
|
(54 |
) |
|
(55 |
) |
|
(179 |
) |
||||
| Net loss attributable to Sangamo Therapeutics, Inc. stockholders | $ |
(1,550 |
) |
$ |
(27,307 |
) |
$ |
(80,392 |
) |
$ |
(99,741 |
) |
||||
| Basic and diluted net loss per common share attributable to Sangamo Therapeutics Inc. stockholders | $ |
(0.01 |
) |
$ |
(0.24 |
) |
$ |
(0.61 |
) |
$ |
(0.90 |
) |
||||
| Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders |
|
141,100 |
|
|
115,710 |
|
|
132,079 |
|
|
110,837 |
|
||||
| Balance Sheet Data: | ||||||
| September 30, 2020 | December 31, 2019 | |||||
| Cash, cash equivalents and marketable securities | $ |
694,588 |
$ |
384,306 |
||
| Total assets |
|
963,710 |
|
637,516 |
||
| Total stockholders' equity |
|
520,881 |
|
432,739 |
||
